{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:31:23Z","timestamp":1792211483296,"version":"4.4.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.arbres.2018.04.010","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T12:57:46Z","timestamp":1526993866000},"page":"592-593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Reacci\u00f3n granulomatosa sarcoidosis-like asociada al tratamiento con inmunoterapia (pembrolizumab)"],"prefix":"10.1016","volume":"54","author":[{"given":"Ignacio","family":"Gay\u00e1 Garc\u00eda-Manso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda del Mar","family":"Garc\u00eda R\u00f3denas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Encarnaci\u00f3n","family":"Barroso Medel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Jos\u00e9","family":"Ill\u00e1n Gamb\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2018.04.010_bib0080","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.arbres.2017.06.016","article-title":"Nueva inmunoterapia y c\u00e1ncer de pulm\u00f3n","volume":"53","author":"S\u00e1nchez de Cos","year":"2017","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2018.04.010_bib0085","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arbres.2018.04.010_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2014-0422","article-title":"The evolving role of immune checkpoint inhibitors in cancer treatment","volume":"20","author":"Pennock","year":"2015","journal-title":"The Oncologist."},{"key":"10.1016\/j.arbres.2018.04.010_bib0095","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities and anti-PD1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol."},{"key":"10.1016\/j.arbres.2018.04.010_bib0100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1634\/theoncologist.2016-0164","article-title":"Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer","volume":"22","author":"O\u2018Kane","year":"2017","journal-title":"The Oncologist."},{"key":"10.1016\/j.arbres.2018.04.010_bib0105","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/S0959-8049(16)30305-7","article-title":"Pneumonitis with anti-PD-1\/PD-L1 therapy","volume":"51","author":"Naidoo","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.arbres.2018.04.010_bib0110","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clindermatol.2007.03.010","article-title":"Sarcoidosis and malignancy","volume":"25","author":"Cohen","year":"2007","journal-title":"Clin Dermatol."},{"key":"10.1016\/j.arbres.2018.04.010_bib0115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000161122","volume":"218","author":"Eckert","year":"2009","journal-title":"Dermatology."},{"key":"10.1016\/j.arbres.2018.04.010_bib0120","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.chest.2015.10.082","article-title":"Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma","volume":"149","author":"Danlos","year":"2016","journal-title":"Chest."},{"key":"10.1016\/j.arbres.2018.04.010_bib0125","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/1078155216667635","article-title":"Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors","volume":"23","author":"Firwana","year":"2017","journal-title":"J Oncol Pharm Pract."},{"key":"10.1016\/j.arbres.2018.04.010_bib0130","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamadermatol.2017.0581","article-title":"Pembrolizumab-induced extensive panniculitis and nevus regression: 2novel cutaneous manifestations of the post-immunotherapy granulomatous reactions spectrum","volume":"153","author":"Burillo-Martinez","year":"2017","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.arbres.2018.04.010_bib0135","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40425-018-0323-0","article-title":"Granulomatous\/sarcoid-like lesions associated with checkpoint inhibitors: A marker of therapy response in a subset of melanoma patients","volume":"6","author":"Tetzlaff","year":"2018","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.arbres.2018.04.010_bib0140","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/annonc\/mdw125","article-title":"Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab","volume":"27","author":"Cousin","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.arbres.2018.04.010_bib0145","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jdcr.2016.06.004","article-title":"Pembrolizumab-associated sarcoidosis","volume":"2","author":"Cotliar","year":"2016","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.arbres.2018.04.010_bib0150","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","article-title":"Management of adverse events following treatment with anti-programmed death-1 agents","volume":"21","author":"Weber","year":"2016","journal-title":"Oncologist"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289618301674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289618301674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T07:51:36Z","timestamp":1604303496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289618301674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0300289618301674"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2018.04.010","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reacci\u00f3n granulomatosa sarcoidosis-like asociada al tratamiento con inmunoterapia (pembrolizumab)","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2018.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}